White paper: A New Paradigm for Manufacturing Injectable Medicines
November 1, 2016 - Uncategorized
Vanrx has released a white paper titled “A New Paradigm for Manufacturing Injectable Medicines,” detailing how Aseptic Filling Workcells support the flexible production of parenteral (injectable) drug products.
This solution resolves long-standing issues in aseptic production, while making manufacturers more agile to react to changing market conditions. Companies that take advantage of the improvements made possible by standardization and automation will bring their drug products to market faster and beat their competition, achieving superior market share and profitability.
The white paper provides a roadmap for manufacturing leaders to modernize their fill-finish operations by adopting the Aseptic Filling Workcell approach, consisting of robotics, automation and gloveless isolator technologies. This approach is supported by the Matrix Alliance, a collaboration between pharmaceutical packaging leaders for product compatibility and testing of nested container and closure systems.
“Every pharmaceutical company, whether they are making novel therapeutics, generics, biosimilars or contract manufacturing is being challenged to produce a more varied portfolio. The products themselves are more complex and address smaller patient populations. Early adopters of this new way of manufacturing will be the winners. They will cut months or years off their launch timelines and be able to change direction quickly via the gains in flexibility and control that are now available,” said Chris Procyshyn, CEO and co-founder of Vanrx.